Brian Engelhardt

February 20, 2020

Post-transplant diabetes may be reversible: study

Post-transplantation diabetes mellitus (PTDM), a common complication of immunosuppressive drugs that are given to prevent transplant rejection, may be reversible and at least partially preventable, researchers at VUMC report.

By Bill Snyder
Dae Kwang Jung, left, Brian Engelhardt, MD, MSCI, and colleagues are studying why stem cell transplant patients are at risk of developing diabetes.
January 17, 2019

Research explores link between stem cell transplant, diabetes

About a decade ago, at the beginning of his career in academic medicine, Brian Engelhardt, MD, MSCI, noticed that many of his patients receiving a stem cell transplant for their blood cancer ended up with diabetes.

By VUMC News and Communications
September 11, 2014

Engelhardt lands stem cell transplant research grant

Up to 60 percent of patients who receive a stem cell transplant using cells from another donor will develop post-transplant diabetes mellitus, which can increase the rate of complications and death after the procedure.

By VUMC News and Communications
April 12, 2012

Targeting post-transplant diabetes

Targeting diabetes that develops after a stem cell transplant may help moderate graft-vs.-host disease, an adverse effect of the procedure, and improve outcomes.

By VUMC News and Communications